Introduction
Autism is a complex neurodevelopmental disorder that appears in the first years of life and persists throughout adulthood. Autism is characterized by qualitative impairment in communication and social interactions, and restricted and stereotyped patterns of behavior, interests, and activities (American Psychiatric Association, 1994) . The disorder is part of a larger group of neuropsychiatric conditions known as autism spectrum disorders (ASDs), which also include Asperger syndrome and pervasive developmental disorder not otherwise specified (PDD-NOS). The prevalence of ASD is six in 1000 individuals, with a male to female ratio of 4 : 1 (Elsabbagh et al., 2012) .
In the last few years, mutations in neurexin and neuroligin (Sudhof, 2008) genes have been found to be associated with ASD and other psychiatric disorders (Jamain et al., 2003; Autism Genome Project Consortium et al., 2007; Kirov et al., 2008) . Neurexins and neuroligins bind transynaptically to regulate important signaling events between presynaptic and postsynaptic terminals, pointing to synaptic defects as a potential pathological mechanism associated with mutations within this system (Sudhof, 2008) . Neurexins are encoded by three genes in humans, each with two alternative promoters, generating the long, alpha, and the short, beta isoforms (Missler and Sudhof, 1998) . b-Neurexins are translated from a translation initiation site encoded by a specific first exon not shared with a isoforms. Recently, we reported two mutations within the NRXN1b-specific exon in patients with autism and mental retardation that affect the translation initiation site. These point mutations involve conserved residues within the Kozak sequence (c.-3G>T) and the start codon (c.3G > T) (Camacho-Garcia et al., 2012) .
In this report, we evaluated the role of rare mutations in the etiology of autism by screening the NRXN1b gene in 153 ASD patients. We identified in one patient a mutation not previously described (c.3G > A; p.Met1) that affects the translation initiation site. Expression studies showed that the c.3G > A mutation changes the initiation site and leads to reduced levels of neurexin-1b protein at the synapse. These results represent an additional evidence for altered synaptic function of neurexin-1b in the risk to autism.
Methods

Patient samples
The autism cohort under study included 153 patients (male : female ratio, 4 : 1; mean age, 17.7 years) who fulfilled the DSM-IV-TR criteria for autism, Asperger disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) on the basis of ADI-R (Autism Diagnostic Interview-Revised) and ADOS-G (Autism Diagnostic Observation Schedule-Generic) (Lord et al., 1994 (Lord et al., , 2000 . Cytogenetic abnormalities and positive Fragile X test were considered as exclusion criteria. The control sample included 400 healthy donors, sex matched with the case sample (mean age: 47.7 years). Patients and controls were Caucasians and Spanish. The study was approved by the relevant ethical committee and written informed consent was obtained from all parents. Genomic DNA was extracted from blood lymphocytes using the salting-out method.
Mutational analysis
Direct sequencing of the coding regions, splice junctions, and of 560 bp of the 5 0 UTR and 131 bp of the 3 0 UTR regions of NRXN1b was performed as reported previously (Camacho-Garcia et al., 2012) . The identified variant was confirmed by an independent PCR amplification and resequencing with 5 0 and 3 0 primers.
Expression and western blot analysis
The pCAGGS vectors expressing human NRXN1b, NRXN1b p.Met1(ATT), NRXN1b
Met1 (ATT)_Met5Ile , and HA-NRXN1b have been reported elsewhere (CamachoGarcia et al., 2012) . A pCAGGS vector expressing NRXN1b p.Met1(ATA) was generated by amplifying the mutationcontaining region from genomic DNA of the patient, which contains the 5 0 UTR and the N-terminal region and replacing the corresponding sequence in the NRXN1b vector. Similarly, pCAG-NRXN1b
Met1(ATA)_Met5Ile was generated by inserting a DNA fragment containing the p.Met1(ATA) mutation into NRXN1b
For expression in cultured neurons, HA-tagged wild type and p.Met1(ATA) NRXN1b were cloned into a lentiviral vector under the control of the human synapsin promoter (Gascon et al., 2008) .
HEK293T cells were transfected with NRXN1b vectors using Lipofectamine (Invitrogen, Carlsbad, California, USA). Twenty-four hours after transfection, cells were analyzed by western blot with a pan-neurexin antibody (Dean et al., 2003) and an a-actin antibody (Sigma, St Louis, Missouri, USA) as described previously (CamachoGarcia et al., 2012) . Data from three independent experiments were evaluated by one-way analysis of variance and Dunn's method for multiple comparisons.
Primary hippocampal cultures were prepared from embryonic day 18 rat brains and plated at a final density of 25 000 cells/cm 2 . For transfection experiments, cultures at 7-9 days in vitro were cotransfected with GFP and HA-NRXN1b or HA-NRXN1b p.Met1(ATA) and analyzed 3 days after transfection. Animal procedures were performed in accordance with institutional and national guidelines for the care and use of laboratory animals following approval by the Ethics Committee of the University of Seville.
Immunofluorescence analysis
Hippocampal cultures fixed with 4% paraformaldehyde and permeabilized with 0.05% Triton X-100 were analyzed by immunofluorescence with synaptobrevin-2 (Synaptic Systems, Gottingen, Germany) and HA (Roche, Basel, Switzerland) antibodies, followed by incubation with secondary antibodies conjugated to Cy3 or Cy5 (Jackson ImmunoResearch Europe Ltd, Suffolk, UK).
Confocal images were captured in a Zeiss LSM 7 Duo microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) using a Â 60 Plan-Apochromat oil immersion objective. The GFP-expressing regions of axonal segments were selected by thresholding, such that the specific HA-neurexin-1b signal was retained. Maximal projections of Z-stacked images were analyzed using ImageJ software (ImageJ, NIH, Bethesda, Maryland, USA). Quantification of HA-neurexin-1b intensity and area at synaptic terminals was performed by selecting synaptobrevin-2 positive clusters within the GFP-transfected axons as regions of interest. Data were obtained from three independent neuronal cultures. Statistical significance was determined using the Mann-Whitney U-test.
Results and discussion
The coding sequence, splice junctions, and the 5 0 UTR and 3 0 UTR regions of the NRXN1b gene were screened for rare variants in a sample of 153 patients with ASD. The only mutation found was a c.3G > A (p.Met1) identified in one male patient (Fig. 1a) . This variant was absent from a control sample of 400 individuals and from the 1000 Genomes and Exome Variant Server datasets. The patient was diagnosed with autistic disorder at the age of 3 years, with language delay and normal-high intellectual capacity (IQ = 125). Segregation analysis showed that the c.3G > A (p.Met1) mutation is maternally inherited and is present in three of the proband's sisters. The mother has a major depression and socialization problems and one of the carriers was diagnosed with anorexia nervosa, whereas the other two carriers did not present any psychiatric trait (Fig. 1b) . Interestingly, mutations in NRXN genes have been described in patients with different psychiatric disorders, although they are also present in asymptomatic relatives (Bucan et al., 2009; Gauthier et al., 2011) . This is in accordance with the multihit model for the molecular basis of this type of disorder, where the phenotype would be the result of the combined effect of several genetic variants.
The mutation described here, p.Met1(ATA), affects the initiation codon of the neurexin-1b, ATG > ATA. The mutated residue is evolutionarily conserved and affects only neurexin-1b, sparing the a-isoform. As the p.Met1(ATA) mutation alters the Met start site, we carried out western blot analysis of transfected cell lysates to evaluate the translation of the mutant protein.
We observed the expression of neurexin-1b p.Met1 (ATA), indicating that translation was not abolished. Interestingly, we had previously identified two different mutations in ASD patients that switch translation initiation of neurexin-1b to a downstream Met codon at position + 5 (Met5). One of the reported mutations also affects the p.Met1 codon, p.Met1(ATT) (CamachoGarcia et al., 2012) . To analyze whether this is also the case for the novel mutation identified here, we generated NRXN1b constructs where Met5 was mutated (p.Met5Ile) and protein expression was analyzed by western blot. The results showed that neurexin-1b expression was inhibited when Met5 was mutated in the context of the p.Met1(ATA) mutant allele ( Fig. 1c and d) . Similar results were obtained with the p.Met1(ATT) mutation, as reported previously (Fig. 1c and d) (Camacho-Garcia et al., 2012) . In contrast, expression was preserved when the Met5 residue was mutated in the wild-type allele ( Fig. 1c and d) . These results suggest that mutation p.Met1(ATA) switches the translation initiation site to Met5, which is not normally used in control individuals.
Neurexins play a role in synapses regulating presynaptic function. To evaluate whether the p.Met1(ATA) mutation affects the synaptic levels of the protein, we generated HA-tagged forms of neurexin-1b by inserting an HA epitope after the signal peptide and transfected cultured hippocampal neurons. Thus, immunofluorescence analysis using an HA antibody allowed us to distinguish transfected neurexin over endogenous proteins. HA-neurexin-1b showed a distribution that partially colocalized with the presynaptic marker synaptobrevin, as shown previously (Fig. 2) . However, expression of HA-neurexin-1b p.Met1(ATA) resulted in a reduction in protein levels in transfected axons. Quantification analysis showed a decrease of B30-40% in the mean intensity and area of HA-neurexin-1b p.Met1(ATA) when compared with HA-neurexin-1b (Fig. 2) . These data indicate that the autism-associated mutation c.3G > A (p.Met1) results in a reduction in the protein levels at the synapse. These results confirm previous data showing that protein translation from the alternative start site at Met5 leads to reduced synaptic levels of neurexin-1b (Camacho-Garcia et al., 2012) .
Conclusion
The novel mutation identified here, c.3G > A (p.Met1), provides an independent confirmation that variants that affect the translation initiation site of neurexin-1b uncover an alternative start codon at Met5. This novel start site is located in a weak consensus initiation sequence that is not the major start site in individuals not bearing the identified change. Translation from this alternative initiation site leads to a reduction in the synaptic levels of neurexin-1b in cultured neurons, reinforcing a dosage effect of neurexins in autism (Toro et al., 2010) .
